You're currently on:

Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs

Availability: In stock.

$20.00
Add Items to Cart
Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs

Description

Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs

Additional Information

Author Michelle Hottinger & Bryan A. Liang
Number 4
Volume 38
Publication AJLM
Journal Year 2012
 

My Cart

You have no items in your shopping cart.